Extending enoxaparin 1 month after hospital discharge reduced thromboembolism after elective hip surgery


Objective
To compare the effectiveness of 1 month of anticoagulant therapy with enoxaparin with enoxaparin given only during hospitalization in patients having elective total hip replacement.

Design
Randomized, double-blind, placebo-controlled trial with maximum 23-day follow-up after discharge from the hospital.

Setting
Hospital in Sweden.

Patients
262 patients who were aged > 39 years (median age 70 y, 57% women) and weighed > 60 kg having elective hip arthroplasty. Exclusion criteria were renal insufficiency; hypersensitivity to contrast medium, heparin, or low-molecular-weight heparin (LMWH); risk for hemorrhage; endocarditis; severe liver disease; untreated hypertension.

Main results
21 patients (18%) receiving enoxaparin developed DVT or pulmonary embolism compared with 45 patients (39%) receiving placebo (P < 0.001). (This absolute risk reduction (ARR) of 21% means that 5 patients would need to be treated (NNT) with enoxaparin (compared with placebo for 1 month to prevent 1 additional patient from developing DVT or pulmonary embolism, 95% CI 3 to 14). The relative risk reduction (RRR) was 54%, CI 28% to 71%).

Conclusion
One month of enoxaparin, compared with enoxaparin alone during hospitalization, led to fewer venous thromboembolic complications in patients having elective hip replacement.

References
1. Planes A, Vochelle N, Darmon J, et al. Thromboembolism after elective hip surgery in the past 6 months; or pregnancy or lactation. 89% of patients were included in the analysis.

Main outcome measures
Deep venous thrombosis (DVT), distal and proximal thrombosis, pulmonary embolism, hemorrhage, and death.

Commentary
The study by Bergqvist and colleagues is the latest in a number of recent randomized trials (1-3) that assess the risk for thromboembolism after hospital discharge and the efficacy of continued prophylaxis with LMWH. Like the previous trials, this study confirmed both the substantial incidence of thrombosis in patients with arthroplasty despite receiving prophylaxis with LMWH until hospital discharge and the reduction in venous thrombosis overall with prolonged prophylaxis. Unlike the recent study by Planes and colleagues (1), however, this study showed a substantial reduction in the incidence of proximal DVT. This difference in results may be because of differences in study design. For instance, Planes and colleagues only randomized patients with normal venography at discharge, and the study had a longer period of in-hospital prophylaxis (13 to 15 d).

The findings by Bergqvist and colleagues raise several clinical issues: Are thrombi found after hospital discharge clinically significant? Does the high incidence of thrombosis despite 4 weeks of prophylaxis suggest that even longer periods of prophylaxis are required? Although this study showed a reduction in the incidence of proximal thrombosis, the placebo group had a higher incidence of proximal DVT (24%) than the placebo group in the study by Planes and colleagues (8%). However, the treatment groups had similar rates. Does this reflect efficacy of prophylaxis after hospital discharge or failure of the shorter period of hospital prophylaxis? The latter possibility has ramifications because of the current trend toward shorter hospital stays.

Until these issues are addressed, optimal duration and method of prophylaxis for patients with arthroplasty after surgery remains to be determined. However, combined with those of previous studies, the results of this trial support a potential benefit for prophylaxis after hospital discharge, especially when patients are discharged shortly after surgery.

Richard M. Jay, MD
Sunnybrook Health Science Centre
Toronto, Ontario, Canada

References